Page last updated: 2024-10-17

bupropion and Obesity

bupropion has been researched along with Obesity in 109 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity."9.51Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022)
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."9.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients."9.22Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."9.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks."9.17A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
" The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women."9.17Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013)
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity."9.14Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010)
"A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain."9.14An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010)
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy."9.14Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009)
"Zonisamide and bupropion have been investigated for weight reduction in obese adults."9.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet."9.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"To critically examine the efficacy of bupropion SR for weight loss."9.10Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002)
"On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women."9.09Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001)
"Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval."8.95Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. ( Halpern, B; Mancini, MC, 2017)
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification."8.93Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016)
" Melatonin, liraglutide, and naltrexone/bupropion are examples of drugs with different mechanisms of action that have favorable effects on obesity or medication-related weight gain."8.91Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. ( Howland, RH, 2015)
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date."8.90Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014)
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination."8.90Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014)
"This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans."8.87Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011)
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia."8.87Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011)
"Bupropion and naltrexone are centrally active drugs that have shown potential efficacy - alone and in combination - for the treatment of obesity."8.85Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009)
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion."8.85Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009)
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone."8.85Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009)
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment."8.31Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023)
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e."7.79Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013)
"The combination of bupropion and naltrexone is one of the most promising new possibilities for the treatment of obesity in an era of increasing prevalence of this disease and decreasing options for its pharmacological management."7.77Bupropion/naltrexone fixed-dose combination for the treatment of obesity. ( Faria, AM; Halpern, A; Halpern, B, 2011)
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials."6.80Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015)
"Insulin resistance was also assessed at the end."6.71Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004)
"The treatment with liraglutide 3."6.66New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. ( Barrea, L; Colao, A; Laudisio, D; Muscogiuri, G; Pugliese, G; Savastano, S, 2020)
"Obesity is an emerging disease worldwide."6.50Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. ( Albert, L; Caixàs, A; Capel, I; Rigla, M, 2014)
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies."6.47Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011)
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit."6.44Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007)
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity."5.51Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022)
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."5.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients."5.22Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016)
"CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks."5.17A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
" The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women."5.17Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."5.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
" Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction."5.14Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009)
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy."5.14Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009)
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity."5.14Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010)
"A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain."5.14An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010)
"Zonisamide and bupropion have been investigated for weight reduction in obese adults."5.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"This study evaluated the ability of polymorphisms in five candidate genes to predict weight gain among patients taking bupropion or placebo in a smoking cessation trial."5.12No evidence for a major role of polymorphisms during bupropion treatment. ( Allison, DB; Berrettini, WH; Hu, J; Lerman, C; Pinto, A; Redden, DT; Restine, SL; Shields, PG, 2006)
"To critically examine the efficacy of bupropion SR for weight loss."5.10Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002)
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet."5.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women."5.09Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001)
"Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease."5.01Gender-related issues in the pharmacology of new anti-obesity drugs. ( Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M, 2019)
" The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population."4.98The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. ( Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K, 2018)
"Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval."4.95Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. ( Halpern, B; Mancini, MC, 2017)
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification."4.93Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016)
" Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates."4.93A Comparison of New Pharmacological Agents for the Treatment of Obesity. ( Megyeri, J; Nuffer, W; Trujillo, JM, 2016)
" In BED with obesity or overweight, bupropion may cause mild weight loss without seizures, and chromium may improve glucose regulation."4.91Psychopharmacologic treatment of eating disorders: emerging findings. ( Guerdjikova, AI; Keck, PE; McElroy, SL; Mori, N, 2015)
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination."4.90Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014)
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date."4.90Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014)
"A short overview of new drugs approved for the treatment of obesity (lorcaserin, phentermine/topiramate combination) as well as those with a perspective for approval as antiobesity drugs (cetilistat, naltrexone/bupropion combination, liraglutide) is presented."4.90Overview of new antiobesity drugs. ( Hainer, V, 2014)
"This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans."4.87Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011)
"Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity."4.87ACS chemical neuroscience molecule spotlight on contrave. ( Mercer, SL, 2011)
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia."4.87Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011)
"In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US."4.86Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. ( , 2010)
"Bupropion and naltrexone are centrally active drugs that have shown potential efficacy - alone and in combination - for the treatment of obesity."4.85Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009)
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone."4.85Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009)
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion."4.85Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009)
" Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance."4.82Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005)
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment."4.31Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023)
"To evaluate the effects of combining topiramate, bupropion and naltrexone in obesity-induced rats on their weight and subcutaneous adipose tissue."4.12Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats. ( Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM, 2022)
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents."4.02Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021)
"The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)."3.83Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016)
" Keywords used to obtain relevant articles included obesity and drug, or orlistat, topiramate/phentermine, lorcaserin, bupropion/naltrexone, and liraglutide."3.83Review of pharmacotherapy options for the management of obesity. ( Bragg, R; Crannage, E, 2016)
"The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood."3.80Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. ( Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R, 2014)
" Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use."3.79Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013)
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e."3.79Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013)
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials."2.80Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015)
" However, they are costly and may have adverse effects in some individuals."2.72Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021)
"Insulin resistance was also assessed at the end."2.71Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004)
"Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes."2.58Medication use for the treatment of diabetes in obese individuals. ( Wilding, JPH, 2018)
"Obesity is a growing epidemic and a major contributor to the global burden of disease."2.52Drug treatment of obesity: current status and future prospects. ( Dahiya, N; Kakkar, AK, 2015)
" Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications."2.52Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015)
"Obesity is a major correlate of cardiovascular disease."2.50Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. ( Cunningham, JW; Wiviott, SD, 2014)
"Over the past decade, treatment for obesity has been limited because of an incomplete understanding of the pathophysiology of obesity, lack of recognition of it as a disease, and limited efficacy of treatment options."2.50Evolving directions in obesity management. ( Aronne, LJ, 2014)
" However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin."2.50Tolerability and safety of the new anti-obesity medications. ( Aldhoon-Hainerová, I; Hainer, V, 2014)
"Obesity is an important causative factor in morbidity, disability and premature death."2.49A review of late-stage CNS drug candidates for the treatment of obesity. ( Gosden, J; Heal, DJ; Smith, SL, 2013)
"The prevalence of obesity is rising worldwide, with the U."2.48Recent advancements in drug treatment of obesity. ( Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J, 2012)
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies."2.47Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011)
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit."2.44Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007)
"Weight gain is cited as a primary reason for not trying to quit smoking."2.42Smoking cessation and weight gain. ( Fernández Pinilla, MC; Fernández-Cruz, A; Filozof, C, 2004)
"Measuring nicotine dependence using the Fagerström Test for Nicotine Dependence may help to define the therapeutic strategy."2.42[Current therapeutic strategies in smoking cessation]. ( Aubin, HJ; Berlin, I; Borgne, A, 2004)
"Obesity is a complex endocrine disease, mainly caused by environmental, behavioral and biological factors."1.62[Pharmacotherapy for obesity]. ( Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS, 2021)
" Central nervous system-active medications have the potential to affect mood; therefore, post hoc analysis of clinical trial data was conducted to evaluate psychiatric adverse events (PAEs) and effects on mood of NB therapy versus placebo."1.51Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. ( Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X, 2019)
"Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30."1.46Obesity Epidemic: Pharmaceutical Weight Loss. ( Curry, SA, 2017)
"Because obesity can affect catecholaminergic signaling, we determined the effects of i."1.34Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007)

Research

Studies (109)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.92)18.7374
1990's0 (0.00)18.2507
2000's23 (21.10)29.6817
2010's73 (66.97)24.3611
2020's12 (11.01)2.80

Authors

AuthorsStudies
Roberto da Silva, G1
Carneiro, MG1
Barbosa, MP1
Costa, JA1
de Souza, IA1
Dos Santos Oliveira, L1
de Vasconcelos, DAA1
do Nascimento, E1
Matos, RJB1
Lopes de Souza, S1
de Freitas, MFL1
Scudeler, MA1
Morreale, S1
Doretto-Silva, L1
Petri, G1
Santos, JFRD1
Nassis, C1
Correa, OMT1
Veridiano, JM1
Grilo, CM3
Lydecker, JA2
Fineberg, SK1
Moreno, JO1
Ivezaj, V1
Gueorguieva, R2
Stefanakis, K1
Kokkinos, A1
Argyrakopoulou, G1
Konstantinidou, SK1
Simati, S1
Kouvari, M1
Kumar, A1
Kalra, B1
Kumar, M1
Bontozoglou, N1
Kyriakopoulou, K1
Mantzoros, CS1
Onakpoya, IJ1
Lee, JJ1
Mahtani, KR1
Aronson, JK1
Heneghan, CJ1
Milano, W1
De Biasio, V1
Di Munzio, W1
Foggia, G1
Capasso, A1
Barrea, L2
Pugliese, G1
Muscogiuri, G2
Laudisio, D1
Colao, A2
Savastano, S2
Brown, SA1
Izzy, M1
Watt, KD1
Morgan, PT1
Tak, YJ1
Lee, SY1
van Rossum, EFC1
Welling, MS1
van der Voorn, B1
van der Valk, ES1
Abawi, O1
van den Akker, ELT1
Wharton, S1
Yin, P1
Burrows, M1
Gould, E1
Blavignac, J1
Christensen, RAG1
Kamran, E1
Camacho, F1
Barakat, M1
Dalton, M1
Finlayson, G1
Walsh, B4
Halseth, AE3
Duarte, C1
Blundell, JE1
Wilding, JPH2
Guerdjikova, AI2
Shan, K2
Dunayevich, E10
McElroy, SL3
Bersoux, S1
Byun, TH1
Chaliki, SS1
Poole, KG1
Cataldi, M1
Guida, B1
Taglialatela, M1
Pi-Sunyer, X1
Apovian, CM3
Acevedo, LM1
Greenway, FL9
Bello, NT2
Chatzis, P1
Tziomalos, K1
Pratilas, GC1
Makris, V1
Sotiriadis, A1
Dinas, K1
Aronne, L1
Rubino, D1
Still, C1
Wyatt, H1
Burns, C3
Kim, D2
Smith, SR2
Fujioka, K12
Gupta, AK3
Billes, SK5
Howland, RH2
White, MA1
Wang, GJ1
Tomasi, D1
Volkow, ND1
Wang, R1
Telang, F1
Caparelli, EC1
Hollander, P1
Plodkowski, R2
Greenway, F1
Bays, H1
Klassen, P2
Sinnayah, P1
Cowley, MA4
Verpeut, JL1
Ueno, H1
Nakazato, M1
Hainer, V2
Aldhoon-Hainerová, I1
Aronne, LJ3
Cunningham, JW1
Wiviott, SD1
Caixàs, A1
Albert, L1
Capel, I1
Rigla, M1
Citrome, L2
Rubio, MA1
Buehler, AM1
Zimmerman, MP1
Mehr, SR1
Kakkar, AK1
Dahiya, N1
Mori, N1
Keck, PE1
Nau, JY1
Greig, SL1
Keating, GM1
Bragg, R1
Crannage, E1
McGinty, EE1
Baller, J1
Azrin, ST1
Juliano-Bult, D1
Daumit, GL1
Kolotkin, RL1
Chen, S1
Gilder, K3
Ali, KF1
Shukla, AP1
Yang, M1
Chen, H1
Johnson, ML1
Essien, EJ1
Peters, RJ1
Wu, IH1
Abughosh, SM1
Nuffer, W1
Trujillo, JM1
Megyeri, J1
Sharfstein, JM1
Psaty, BM1
Nissen, SE1
Wolski, KE1
Prcela, L1
Wadden, T1
Buse, JB1
Bakris, G1
Perez, A1
Tolles, J1
Lewis, RJ1
Wise, J1
Alfaris, N1
Kyle, TK1
Nadai, J1
Stanford, FC1
O'Neil, PM3
Hong, K1
Herrmann, K1
Dybala, C1
Lam, H1
Foreyt, JP2
Braverman-Panza, J1
Halpern, B2
Mancini, MC1
Stefanidis, A1
Man Lee, CC1
Brown, WA1
Oldfield, BJ1
Halseth, A1
Igel, LI1
Kumar, RB1
Saunders, KH1
Curry, SA1
Kapoor, S1
Whitehouse, MJ1
Guttadauria, M3
Anderson, JW2
Atkinson, RL1
Gadde, KM6
O'Neil, P1
Schumacher, D1
Smith, D1
Tollefson, GD1
Weber, E1
Plodkowski, RA2
Nguyen, Q1
Sundaram, U1
Nguyen, L1
Chau, DL1
St Jeor, S1
Lee, MW1
Padwal, R1
Tollefson, G2
Erickson, J2
Wilcox, CS1
Oskooilar, N1
Erickson, JS2
Katz, BB1
Kaplan, LM1
Wadden, TA2
Foster, GD1
Hill, JO1
Klein, S1
Perri, MG1
Pi-Sunyer, FX1
Rock, CL1
Maier, HN1
Kim, DD2
Mudaliar, S1
Astrup, A1
Katsiki, N1
Hatzitolios, AI1
Mikhailidis, DP1
Faria, AM1
Halpern, A1
Bray, GA1
Ryan, DH1
Makowski, CT1
Gwinn, KM1
Hurren, KM1
Hiatt, WR1
Thomas, A1
Goldfine, AB1
Heal, DJ1
Gosden, J1
Smith, SL1
Mercer, SL1
Carter, R1
Mouralidarane, A1
Ray, S1
Soeda, J1
Oben, J1
Clapper, JR1
Athanacio, J1
Wittmer, C1
Griffin, PS1
D'Souza, L1
Parkes, DG1
Roth, JD1
Jain, AK1
Kaplan, RA1
Allison, DB2
Brewer, ER1
Leadbetter, RA1
Richard, N1
Haight, B1
Jamerson, BD1
Buaron, KS1
Metz, A1
Botella-Carretero, JI1
Escobar-Morreale, HF1
Martín, I1
Valero, AM1
Alvarez, F1
García, G1
Varela, C1
Cantarero, M1
Filozof, C1
Fernández Pinilla, MC1
Fernández-Cruz, A1
Shekelle, PG1
Morton, SC1
Maglione, M1
Suttorp, M1
Tu, W1
Li, Z1
Maggard, M1
Mojica, WA1
Shugarman, L1
Solomon, V1
Borgne, A1
Aubin, HJ1
Berlin, I1
Carter, GT1
Yudkowsky, MP1
Han, JJ1
McCrory, MA1
Zimmerman, M1
Posternak, MA1
Attiullah, N1
Friedman, M1
Boland, RJ1
Baymiller, S1
Berlowitz, SL1
Rahman, S1
Uy, KK1
Singer, S1
Chelminski, I1
Menaster, MJ1
McCreadie, R1
Hu, J1
Redden, DT1
Berrettini, WH1
Shields, PG1
Restine, SL1
Pinto, A1
Lerman, C1
Xiong, GL1
Ramseier, CA1
Bornstein, MM1
Saxer, UP1
Klingler, K1
Walter, C1
Yonish, GM1
Foust, MS1
Wagner, HR2
Aylwin, S1
Al-Zaman, Y1
Parker, CB1
Maner, LG1
Logue, EJ1
Drezner, MK1
Krishnan, KR1
McKenney, J1
Nobrega, JN1
Coscina, DV1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo[NCT02317744]22 participants (Actual)Interventional2014-12-31Completed
The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits[NCT04614545]Phase 470 participants (Actual)Interventional2021-01-01Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255]Phase 31,496 participants (Actual)Interventional2007-12-31Completed
Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167]Phase 2/Phase 361 participants (Actual)Interventional2005-12-31Completed
Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects[NCT00711477]Phase 246 participants (Actual)Interventional2008-09-30Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630]Phase 3505 participants (Actual)Interventional2007-05-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR[NCT01601704]Phase 38,910 participants (Actual)Interventional2012-06-30Terminated
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386]Phase 3242 participants (Actual)Interventional2013-02-28Completed
Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731]Phase 2/Phase 3120 participants (Anticipated)Interventional2006-11-30Recruiting
The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy[NCT02627105]120 participants (Actual)Interventional2015-09-30Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program[NCT00456521]Phase 3793 participants (Actual)Interventional2007-03-31Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00532779]Phase 31,742 participants (Actual)Interventional2007-10-31Completed
Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230]0 participants (Actual)Interventional2013-11-30Withdrawn (stopped due to failure to enroll)
WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study[NCT03714971]127 participants (Actual)Interventional2017-03-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Interventionbinge eating days (out of 28) (Mean)
Naltrexone/ Bupropion Combination5.4
Pill Placebo2.9

Binge Eating Frequency (Continuous)

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Interventionbinge eating days (out of 28) (Mean)
Naltrexone/ Bupropion Combination4.4
Pill Placebo3.0

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)

Interventionkg/m^2 (Mean)
Naltrexone/ Bupropion Combination35.9
Pill Placebo40.3

Body Mass Index (BMI)

BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)

Interventionkg/m^2 (Mean)
Naltrexone/ Bupropion Combination34.5
Pill Placebo39.7

Adherence to Medication Use

Percentage of patients that took the medication as prescribed (NCT04614545)
Timeframe: 12 weeks

InterventionPercentage of pts completed medication (Number)
Virtual Visits93.3
Face to Face Visits83.3

Adherence to Weight Management Program

Assessed as percentage of patients who completed all visits (NCT04614545)
Timeframe: 12 weeks

InterventionPercentage of completed patients (Number)
Virtual Visits82.9
Face to Face Visits62.9

Change in Body Weight (Percentage)

The primary endpoint is mean change in body weight (%) from baseline (visit 1) to 12 weeks (visit 4) in body weight. (NCT04614545)
Timeframe: 12 weeks

Interventionmean change in body weight (%) (Mean)
Virtual Visits-6.61
Face to Face Visits-7.68

Percentage of Patients That Tolerated Full Dosage of Phentermine (37.5mg)

(NCT04614545)
Timeframe: 12 weeks

InterventionPercentage of patients on full dose (Number)
Virtual Visits85.7
Face to Face Visits90

Percentage of Patients Who Achieved More Than 5% Weight Loss Over the Course of the Study (12 Weeks)

(NCT04614545)
Timeframe: 12 weeks

InterventionPercentage of patients with >5% wt loss (Number)
Virtual Visits64.7
Face to Face Visits70.5

Body Weight- Mean Percent Change From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-6.40
Placebo-1.23

Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of participants (Number)
NB3227.27
Placebo7.02

Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3250.48
Placebo17.11

Change in Diastolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmm Hg (Least Squares Mean)
NB320.20
Placebo-0.67

Change in Fasting Blood Glucose Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB32-2.11
Placebo-1.73

Change in Fasting HDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB321.19
Placebo-1.40

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-14.14
Placebo-0.50

Change in Fasting LDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB32-4.36
Placebo0.00

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-7.32
Placebo-1.36

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.68
Placebo-2.20

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-3.20
Placebo-3.18

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-9.38
Placebo-1.14

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-16.44
Placebo-4.15

Change in IDS-SR Total Score

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-0.23
Placebo-0.28

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB329.94
Placebo6.17

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-18.32
Placebo-11.09

Change in Systolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmm Hg (Least Squares Mean)
NB32-0.93
Placebo-1.23

Change in Waist Circumference

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventioncm (Least Squares Mean)
NB32-6.16
Placebo-2.74

Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-6.45
Placebo-1.89

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of participants (Number)
NB3255.64
Placebo17.54

Frequency of Binge Eating Episodes

(NCT00414167)
Timeframe: One week (at post treatment)

Interventionepisodes/week (Mean)
Bupropion0.8
Placebo1.0

Percent BMI Loss

Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)

InterventionPercent loss (Mean)
Bupropion1.8
Placebo0.6

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-13.55
Placebo-4.14

Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.16
Placebo0.48

Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-0.90
Placebo0.45

Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.64
Placebo-0.16

Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB321.47
Placebo1.87

Percent Change in Body Weight

(NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-0.99
Placebo-0.43

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.42
NB320.16

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.16
NB320.60

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.79
NB320.21

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.16
NB320.30

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.35
NB320.34

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.56
NB320.74

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3218.49
Placebo5.66

Change in Diastolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB32-1.06
Placebo-1.47

Change in Fasting Blood Glucose Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-11.87
Placebo-4.02

Change in Fasting HDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB323.03
Placebo-0.29

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-13.48
Placebo-10.35

Change in Fasting LDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-1.44
Placebo-0.01

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-11.20
Placebo-0.80

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.48
Placebo-1.52

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.97
Placebo-2.40

Change in HbA1c Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent (Least Squares Mean)
NB32-0.63
Placebo-0.14

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.91
Placebo-13.29

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.56
Placebo-14.67

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB320.01
Placebo-1.60

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB329.27
Placebo7.90

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-11.89
Placebo-6.91

Change in Systolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB320.03
Placebo-1.12

Change in Waist Circumference

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB32-4.97
Placebo-2.89

Co-primary: Body Weight- Mean Percent Change

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-5.03
Placebo-1.75

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.53
Placebo18.87

HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3220.72
Placebo10.22

HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.14
Placebo26.28

Percent of Subjects Discontinuing Due to Poor Glycemic Control

Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB320
Placebo1.89

Percent of Subjects Requiring Rescue Medications for Diabetes

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3222.26
Placebo35.22

Percent of Subjects With Dose Increase in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB323.02
Placebo1.26

Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB321.89
Placebo1.26

Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

InterventionParticipants (Count of Participants)
NB3217
Placebo34

Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

InterventionParticipants (Count of Participants)
NB32133
Placebo142

Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)

The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

InterventionParticipants (Count of Participants)
NB3290
Placebo102

Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

InterventionParticipants (Count of Participants)
NB3255
Placebo57

Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal)

Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up

InterventionParticipants (Count of Participants)
NB3222
Placebo21

Absolute Change in Body Weight From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionkg (Least Squares Mean)
NB + CLI-9.7
Usual Care-1.0

Change Fasting Insulin From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

InterventionuIU/mL (Least Squares Mean)
NB + CLI-7.5
Usual Care-3.4

Change in Diastolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-1.7
Usual Care-1.3

Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI4.1
Usual Care0.1

Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.0
Usual Care-1.9

Change in Fasting Plasma Glucose From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.9
Usual Care1.6

Change in Fasting Triglycerides From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-13.6
Usual Care2.8

Change in Heart Rate From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionbpm (Least Squares Mean)
NB + CLI1.7
Usual Care-0.3

Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26

HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.0
Usual Care-0.8

Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26

Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.2
Usual Care-0.1

Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26

The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-6.8
Usual Care1.1

Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26

Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI16.4
Usual Care-1.0

Change in Systolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-4.8
Usual Care-2.8

Change in Waist Circumference From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventioncm (Least Squares Mean)
NB + CLI-6.96
Usual Care-1.64

Percent Change in Body Weight From Baseline (Day 1) to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercent change in body weight (Least Squares Mean)
NB + CLI-9.46
Usual Care-0.94

Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI42.3
Usual Care3.7

Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI12.7
Usual Care0.0

Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI84.5
Usual Care12.2

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3241.49
Placebo20.21

Change in Diastolic Blood Pressure

(NCT00456521)
Timeframe: Baseline, 56 weeks

InterventionmmHg (Least Squares Mean)
NB32-1.41
Placebo-2.78

Change in Fasting Blood Glucose Levels

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-2.36
Placebo-1.08

Change in Fasting HDL Cholesterol Levels

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB324.10
Placebo0.87

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-27.98
Placebo-15.45

Change in Fasting LDL Cholesterol

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB325.43
Placebo8.13

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-16.62
Placebo-8.51

Change in Food Craving Inventory Carbohydrates Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.06
Placebo-1.97

Change in Food Craving Inventory Sweets Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.54
Placebo-2.43

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-25.87
Placebo-16.89

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-29.93
Placebo-16.56

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB320.09
Placebo-0.00

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB3213.43
Placebo10.29

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-13.75
Placebo-8.46

Change in Systolic Blood Pressure

(NCT00456521)
Timeframe: Baseline, 56 weeks

InterventionmmHg (Least Squares Mean)
NB32-1.32
Placebo-3.87

Change in Waist Circumference

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB32-9.98
Placebo-6.77

Co-primary: Body Weight- Mean Percent Change

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-9.29
Placebo-5.08

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3266.39
Placebo42.49

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00532779)
Timeframe: Baseline, 56 weeks

InterventionPercentage of participants (Number)
NB1620.17
NB3224.63
Placebo7.44

Change in Diastolic Blood Pressure

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB160.09
NB320.04
Placebo-0.86

Change in Fasting Blood Glucose Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB16-2.39
NB32-3.24
Placebo-1.30

Change in Fasting HDL Cholesterol Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB163.36
NB323.42
Placebo-0.06

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-11.84
NB32-17.14
Placebo-4.57

Change in Fasting LDL Cholesterol Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB16-3.67
NB32-4.41
Placebo-3.28

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-7.96
NB32-12.69
Placebo-3.08

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-1.85
NB32-2.11
Placebo-1.84

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-2.08
NB32-2.62
Placebo-2.77

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-28.02
NB32-28.98
Placebo-16.66

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-14.33
NB32-20.19
Placebo-5.90

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB160.02
NB32-0.27
Placebo-0.72

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB1611.68
NB3212.69
Placebo8.55

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-12.49
NB32-14.52
Placebo-8.68

Change in Systolic Blood Pressure

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB160.29
NB32-0.11
Placebo-1.94

Change in Waist Circumference

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB16-5.04
NB32-6.24
Placebo-2.46

Co-primary: Body Weight- Mean Percent Change

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB16-5.00
NB32-6.14
Placebo-1.33

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB1639.49
NB3247.98
Placebo16.44

Reviews

46 reviews available for bupropion and Obesity

ArticleYear
Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.
    British journal of clinical pharmacology, 2020, Volume: 86, Issue:4

    Topics: Bupropion; Drug Combinations; Humans; Naltrexone; Obesity

2020
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8

    Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity;

2020
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Minerva endocrinologica, 2020, Volume: 45, Issue:2

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Endocrinology; Humans; Liraglutide; Naltrexone; N

2020
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liv

2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Current obesity reports, 2021, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl

2021
Medication use for the treatment of diabetes in obese individuals.
    Diabetologia, 2018, Volume: 61, Issue:2

    Topics: Animals; Benzazepines; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Lacton

2018
Pharmacotherapy for obesity: What you need to know.
    Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans

2017
Gender-related issues in the pharmacology of new anti-obesity drugs.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; F

2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Folia medica, 2018, Dec-01, Volume: 60, Issue:4

    Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Li

2018
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Pharmacological research, 2014, Volume: 84

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; H

2014
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:6

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Nal

2014
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical

2014
Tolerability and safety of the new anti-obesity medications.
    Drug safety, 2014, Volume: 37, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related

2014
Overview of new antiobesity drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Li

2014
Evolving directions in obesity management.
    The Journal of family practice, 2014, Volume: 63, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Forecasting; Glucagon-Like Peptide 1; Gl

2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Clinical cardiology, 2014, Volume: 37, Issue:11

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dru

2014
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity

2014
Drug treatment of obesity: current status and future prospects.
    European journal of internal medicine, 2015, Volume: 26, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose

2015
Psychopharmacologic treatment of eating disorders: emerging findings.
    Current psychiatry reports, 2015, Volume: 17, Issue:5

    Topics: Administration, Intranasal; Anorexia Nervosa; Anti-Obesity Agents; Antidepressive Agents, Second-Gen

2015
Safety and tolerability of medications approved for chronic weight management.
    Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects

2015
Current and emerging medications for overweight or obesity in people with comorbidities.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11

    Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem

2015
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:6

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesi

2015
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Drugs, 2015, Volume: 75, Issue:11

    Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Huma

2015
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
    Schizophrenia bulletin, 2016, Volume: 42, Issue:1

    Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine

2016
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Expert review of clinical pharmacology, 2016, Volume: 9, Issue:1

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Approval; Drug Combinatio

2016
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Future cardiology, 2016, Volume: 12, Issue:2

    Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrex

2016
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations

2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:1

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; H

2017
Practical Use of Pharmacotherapy for Obesity.
    Gastroenterology, 2017, Volume: 152, Issue:7

    Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents

2017
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:6

    Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Co

2009
Naltrexone for the treatment of obesity: review and update.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:11

    Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans;

2009
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:10

    Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Act

2009
Pharmacologic therapies for obesity.
    Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1

    Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes;

2010
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs in R&D, 2010, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Bupropion; Clinical Trials, Phase II as Topic; Clinical Trials, Phase

2010
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Annals of medicine, 2011, Volume: 43, Issue:4

    Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type

2011
Combination therapy with naltrexone and bupropion for obesity.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11

    Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Anta

2011
Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Obesity facts, 2011, Volume: 4, Issue:6

    Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; H

2011
A review of late-stage CNS drug candidates for the treatment of obesity.
    International journal of obesity (2005), 2013, Volume: 37, Issue:1

    Topics: Anti-Obesity Agents; Bupropion; Central Nervous System Stimulants; Drug Administration Schedule; Dru

2013
ACS chemical neuroscience molecule spotlight on contrave.
    ACS chemical neuroscience, 2011, Sep-21, Volume: 2, Issue:9

    Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Appro

2011
Recent advancements in drug treatment of obesity.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinati

2012
Smoking cessation and weight gain.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2004, Volume: 5, Issue:2

    Topics: Body Composition; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; In

2004
Pharmacological and surgical treatment of obesity.
    Evidence report/technology assessment (Summary), 2004, Issue:103

    Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric

2004
[Current therapeutic strategies in smoking cessation].
    La Revue du praticien, 2004, Nov-15, Volume: 54, Issue:17

    Topics: Administration, Cutaneous; Bupropion; Chewing Gum; Cognitive Behavioral Therapy; Dopamine Uptake Inh

2004
Why isn't bupropion the most frequently prescribed antidepressant?
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5

    Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion;

2005
Bupropion for weight reduction.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio

2007
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria

2008

Trials

21 trials available for bupropion and Obesity

ArticleYear
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
    The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12

    Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middl

2022
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Clinical therapeutics, 2021, Volume: 43, Issue:1

    Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug

2021
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5

    Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin

2013
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:4

    Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female;

2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro

2013
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Clinical obesity, 2015, Volume: 5, Issue:5

    Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; N

2015
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    JAMA, 2016, Mar-08, Volume: 315, Issue:10

    Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Conf

2016
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
    International journal of obesity (2005), 2016, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male;

2016
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Clinical obesity, 2016, Volume: 6, Issue:5

    Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr

2016
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors;

2017
Rational design of a combination medication for the treatment of obesity.
    Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:1

    Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy,

2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12

    Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Met

2009
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
    Addictive behaviors, 2010, Volume: 35, Issue:3

    Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Femal

2010
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741

    Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therap

2010
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Obesity research, 2002, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa

2002
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2004, Volume: 36, Issue:3

    Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol

2004
No evidence for a major role of polymorphisms during bupropion treatment.
    Obesity (Silver Spring, Md.), 2006, Volume: 14, Issue:11

    Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Genetic Predisposition to

2006
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:8

    Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma

2007
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
    Obesity research, 2001, Volume: 9, Issue:9

    Topics: Adult; Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Adminis

2001
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
    Obesity research, 2002, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Constitution; Bupropion; Cholesterol, HDL; De

2002

Other Studies

42 other studies available for bupropion and Obesity

ArticleYear
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats.
    The Journal of endocrinology, 2022, 04-13, Volume: 253, Issue:3

    Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats;

2022
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.
    Einstein (Sao Paulo, Brazil), 2022, Volume: 20

    Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiram

2022
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9

    Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Human

2023
[Pharmacotherapy for obesity].
    Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165

    Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Dru

2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    International journal of obesity (2005), 2021, Volume: 45, Issue:8

    Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl

2021
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
    International journal of obesity (2005), 2017, Volume: 41, Issue:8

    Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding

2017
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
    Advances in therapy, 2017, Volume: 34, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bup

2017
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
    Clinical obesity, 2018, Volume: 8, Issue:3

    Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans;

2018
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
    International journal of obesity (2005), 2019, Volume: 43, Issue:10

    Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Nalt

2019
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:7

    Topics: Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone;

2019
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9

    Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptak

2013
Therapies for obesity and medication-associated weight gain.
    Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5

    Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined

2013
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.
    International journal of obesity (2005), 2014, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combin

2014
Contrave--a combination of bupropion and naltrexone for weight loss.
    The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455

    Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrex

2014
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2014, Volume: 68, Issue:12

    Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesit

2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10

    Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug A

2014
Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Anti-Obesity Agents; Bupropion; Humans; Naltrexone; Obesity

2015
Nonincretin drugs in later-stage development.
    The American journal of managed care, 2014, Volume: 20, Issue:1 Spec No.

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs,

2014
[Mysimba, an American appetite suppressant and the logic of the single European market].
    Revue medicale suisse, 2015, Apr-15, Volume: 11, Issue:470

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight

2015
Review of pharmacotherapy options for the management of obesity.
    Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2

    Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Ob

2016
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers.
    Substance use & misuse, 2015, Volume: 50, Issue:13

    Topics: Adolescent; Adult; Aged; Bupropion; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dopamine

2015
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
    JAMA, 2016, Mar-08, Volume: 315, Issue:10

    Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal

2016
Time-to-Event Analysis.
    JAMA, 2016, Mar-08, Volume: 315, Issue:10

    Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal

2016
Company is blamed for early halt of trial into obesity treatment.
    BMJ (Clinical research ed.), 2016, Mar-08, Volume: 352

    Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Femal

2016
A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity.
    International journal of obesity (2005), 2016, Volume: 40, Issue:9

    Topics: Anti-Obesity Agents; Attitude of Health Personnel; Behavior, Addictive; Bupropion; Drug Therapy, Com

2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones

2016
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model.
    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017, Volume: 13, Issue:2

    Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distr

2017
Obesity Epidemic: Pharmaceutical Weight Loss.
    Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans;

2017
Strategies to control antipsychotic-induced weight gain.
    Psychoneuroendocrinology, 2008, Volume: 33, Issue:8

    Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F

2008
Is cardiometabolic risk improved by weight-loss drugs?
    Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741

    Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexo

2010
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    International journal of clinical practice, 2010, Volume: 64, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparation

2010
New obesity pill: new hopes, old fears.
    Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758

    Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; D

2010
Bupropion/naltrexone fixed-dose combination for the treatment of obesity.
    Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:8

    Topics: Animals; Bupropion; Clinical Trials as Topic; Drug Combinations; Humans; Naltrexone; Obesity

2011
Drug treatment of obesity.
    The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4

    Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupro

2011
What cost weight loss?
    Circulation, 2012, Mar-06, Volume: 125, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P

2012
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
    European journal of pharmacology, 2013, Jan-05, Volume: 698, Issue:1-3

    Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Ea

2013
Topiramate for weight reduction in Duchenne muscular dystrophy.
    Muscle & nerve, 2005, Volume: 31, Issue:6

    Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bu

2005
Weight gain, sexual dysfunction, and bupropion.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans;

2005
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:4

    Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug

2007
Editorial.
    Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:4

    Topics: Body Mass Index; Bupropion; Depression; Dopamine Uptake Inhibitors; Health Behavior; Humans; Life St

2006
[Tobacco use prevention and cessation in the dental practice].
    Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia, 2007, Volume: 117, Issue:3

    Topics: Behavior Therapy; Benzazepines; Bupropion; Dentist-Patient Relations; Health Plan Implementation; Hu

2007
Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
    Pharmacology, biochemistry, and behavior, 1986, Volume: 25, Issue:2

    Topics: Animals; Body Weight; Brain Mapping; Bupropion; Dopamine; Feeding Behavior; Female; Hydroxydopamines

1986